Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M53,819Revenue $M20,174Net Margin (%)12.6Altman Z-Score2.2
Enterprise Value $M65,316EPS $3.0Operating Margin %17.2Piotroski F-Score5
P/E(ttm)21.6Beneish M-Score-2.8Pre-tax Margin (%)15.3Higher ROA y-yY
Price/Book2.410-y EBITDA Growth Rate %14.6Quick Ratio0.6Cash flow > EarningsY
Price/Sales2.75-y EBITDA Growth Rate %4.7Current Ratio0.9Lower Leverage y-yN
Price/Free Cash Flow14.5y-y EBITDA Growth Rate %-7.3ROA % (ttm)5.4Higher Current Ratio y-yN
Dividend Yield %2.1PEG4.7ROE % (ttm)11.0Less Shares Outstanding y-yN
Payout Ratio %46.0Shares Outstanding M839ROIC % (ttm)8.8Gross Margin Increase y-yY

Gurus Latest Trades with TEVA

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TEVAJohn Paulson 2015-06-30 Buy 0.57%$58.91 - $67.14
($61.7)
$ 65.286%New holding2,030,500
TEVANWQ Managers 2015-06-30 Reduce-0.53%$58.91 - $67.14
($61.7)
$ 65.286%Reduce 18.66%2,984,606
TEVAGeorge Soros 2015-06-30 Buy 0.26%$58.91 - $67.14
($61.7)
$ 65.286%New holding423,308
TEVAVanguard Health Care Fund 2015-06-30 Sold Out -0.25%$58.91 - $67.14
($61.7)
$ 65.286%Sold Out0
TEVAFirst Eagle Investment 2015-06-30 Reduce-0.07%$58.91 - $67.14
($61.7)
$ 65.286%Reduce 10.66%3,756,998
TEVADavid Dreman 2015-06-30 Reduce-0.05%$58.91 - $67.14
($61.7)
$ 65.286%Reduce 9.77%90,345
TEVAJames Barrow 2015-06-30 Reduce-0.03%$58.91 - $67.14
($61.7)
$ 65.286%Reduce 3.21%9,862,843
TEVARonald Muhlenkamp 2015-06-30 Add$58.91 - $67.14
($61.7)
$ 65.286%Add 0.12%176,915
TEVACharles Brandes 2015-06-30 Sold Out $58.91 - $67.14
($61.7)
$ 65.286%Sold Out0
TEVAJohn Keeley 2015-06-30 Reduce$58.91 - $67.14
($61.7)
$ 65.286%Reduce 1.51%36,280
TEVAGeorge Soros 2015-03-31 Sold Out -3.1%$54.93 - $62.65
($58.14)
$ 65.2812%Sold Out0
TEVAVanguard Health Care Fund 2015-03-31 Reduce-0.41%$54.93 - $62.65
($58.14)
$ 65.2812%Reduce 61.47%1,896,960
TEVAFirst Eagle Investment 2015-03-31 Add0.26%$54.93 - $62.65
($58.14)
$ 65.2812%Add 71.77%4,205,481
TEVANWQ Managers 2015-03-31 Reduce-0.24%$54.93 - $62.65
($58.14)
$ 65.2812%Reduce 8.53%3,669,079
TEVADavid Dreman 2015-03-31 Reduce-0.09%$54.93 - $62.65
($58.14)
$ 65.2812%Reduce 16.44%100,133
TEVAJames Barrow 2015-03-31 Reduce-0.05%$54.93 - $62.65
($58.14)
$ 65.2812%Reduce 5.85%10,189,904
TEVAMichael Price 2015-03-31 Reduce-0.05%$54.93 - $62.65
($58.14)
$ 65.2812%Reduce 1.61%440,300
TEVARonald Muhlenkamp 2015-03-31 Add$54.93 - $62.65
($58.14)
$ 65.2812%Add 0.18%176,710
TEVAJohn Keeley 2015-03-31 Reduce$54.93 - $62.65
($58.14)
$ 65.2812%Reduce 2.95%36,835
TEVATom Gayner 2014-12-31 Sold Out -0.67%$49.86 - $58.72
($55.72)
$ 65.2817%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TEVA is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TEVA: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about TEVA:

    News about TEVA:

    Articles On GuruFocus.com
    Daniel Loeb's Third Point Second Quarter Investor Letter Aug 03 2015 
    Weekly 52-Week Highs Highlight: GIS, AAP, BCR, TEVA Jul 28 2015 
    Paul Tudor Jones Buys Stakes in ADP and Visa Jun 19 2015 
    KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
    Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks Jun 11 2015 
    Leon Cooperman's Top Holdings Look Attractive Jun 09 2015 
    Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
    Big Pharma Companies Are Betting On Regenerative Medicine - Should You? May 26 2015 
    Stanley Druckenmiller's Top 5 New Stocks May 25 2015 
    Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 

    More From Other Websites
    Endo International: Uncertain Growth Beyond 2017? Sep 01 2015
    Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic transdermal system), First... Sep 01 2015
    Teva Announces U.S. Availability of ZECUITY® (sumatriptan iontophoretic transdermal system), First... Sep 01 2015
    Mylan Shareholders Back Proposal to Buy Perrigo Aug 28 2015
    Mylan shareholders approve acquisition of Perrigo Aug 28 2015
    Short Sellers Have Mixed Feelings on Major Pharma Aug 26 2015
    Lilly Says Court Ruled in its Favor on Patent Aug 25 2015
    Put Impax, Akorn and Sagent on Your Watch List of Generics Targets Aug 25 2015
    10 Stocks George Soros Is Buying in 2015 Aug 25 2015
    10 Stocks Billionaire John Paulson Is Buying in 2015 Aug 24 2015
    Dozens stage protest outside Teva's North American HQ Aug 20 2015
    Mylan Comments on Teva's Agreement to Acquire Allergan's Generic Drug Unit Aug 18 2015
    Generic-Drug Firms That May Be Swallowed Up Aug 14 2015
    Teva Pharmaceutical Industries Ltd. Earnings Q2*, 2015 Aug 14 2015
    Teva's Chorea in Huntington Disease Treatment under Review Aug 13 2015
    4 More Recession Stocks to Consider for Volatile Times Aug 13 2015
    The Chemical Works of Gedeon Richter Plc Earnings Q2*, 2015 Aug 13 2015
    Faber Report: Mylan persists with battle for Perrigo Aug 13 2015
    Mylan pursues Perrigo with lower shareholder support for takeover Aug 13 2015
    Always a good time for M&A until it's not: Pro Aug 12 2015
    Takeda Pharmaceutical Co., Ltd. Earnings Q2*, 2015 Aug 12 2015
    Short Sellers Back Off Big Pharma Aug 12 2015
    Teva Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease Aug 12 2015
    Teva Announces FDA Acceptance of NDA for SD-809 for Treatment in Huntington Disease Aug 12 2015
    Teva and Immuneering Announce Teva’s Purchase of 51% Equity Share of Genomic-Analysis Company Aug 03 2015
    Teva Secures $33.75 Billion Financing Commitment Jul 31 2015
    Amgen hikes 2015 forecast after 2Q increase in profit, sales Jul 30 2015
    Teva Reports Strong Second Quarter 2015 Results and Raises Guidance for Full-Year 2015 Jul 30 2015
    More tie-ups in generic drug cos expected Jul 28 2015
    Teva Announces European Medicines Agency (EMA) Confirms Successful Validation of Reslizumab... Jul 28 2015
    Mylan independence from Teva's embrace comes with a price Jul 27 2015
    Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
    Allergan CEO, fresh off one deal, sets sights on others Jul 27 2015
    Analysts expect more tie-ups in generic drug business Jul 27 2015
    Chinese market dive pressures US stocks Jul 27 2015
    Teva and Restaurant Brands are big market movers Jul 27 2015
    Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid Jul 27 2015
    Israel's Teva buys Allergan generic drug company for $40.5B Jul 27 2015
    Chinese market dive pressures US stocks Jul 27 2015
    Teva Reports Preliminary Second Quarter 2015 Results Jul 27 2015
    Teva Withdraws Proposal to Acquire Mylan Jul 27 2015
    Teva to Acquire Allergan Generics for $40.5 Billion Creating a Transformative Generics and Specialty... Jul 27 2015
    Israel's Teva Pharmaceutical to buy Allergan's generic pharmaceuticals business for $40.5B Jul 27 2015
    Allergan to acquire Naurex as Teva talks continue Jul 26 2015
    Teva nears deal for Allergan's generic drugs unit - source Jul 25 2015
    Teva in talks to buy Allergan big generic-drug unit - WSJ Jul 25 2015
    Mylan puts up barrier to Teva with Dutch legal maneuver Jul 23 2015
    Teva Issues Statement Jul 23 2015
    Teva to Report Second Quarter 2015 Financial Results on July 30, 2015 Jul 21 2015
    Teva First to Receive Approval and Launch Generic Axert® Tablets in the United States Jul 08 2015
    Teva to lift bid for Mylan: report Jul 06 2015
    Teva and Xenon Provide Update on TV-45070 Phase 2b Study in Osteoarthritis Pain Jul 01 2015
    Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO... Jun 25 2015
    Teva takes 4.6 percent stake in Mylan as part of bid Jun 19 2015
    Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V. Jun 19 2015
    Teva to Present New Findings at the American Headache Society (AHS) Meeting – Analysis of Migraine... Jun 18 2015
    Big shareholder backs drugmaker Mylan's growth strategy Jun 16 2015
    Teva accuses Mylan of 'desperate attempt' to suppress bid Jun 08 2015
    Exclusive - Teva poised to raise its stake in Mylan -sources Jun 02 2015
    Exclusive - Teva poised to raise its stake in Mylan: sources Jun 02 2015
    Teva to pay $1.2 billion in drug-delay settlement May 28 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK